Autolus Therapeutics
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 471
- Market Cap
- $1B
- Website
- http://www.autolus.com
- Introduction
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
Autolus Reports Promising Long-Term Data for Obe-cel in Relapsed/Refractory B-ALL at EHA Congress
Autolus Therapeutics presented updated clinical data showing 40% of responders to obecabtagene autoleucel (obe-cel) maintained remission for ≥3 years without subsequent stem cell therapy, suggesting potential as a definitive treatment for r/r B-ALL.
Agilent's xCELLigence Technology Plays Critical Role in FDA Approval of Autolus' CAR T Therapy
Agilent Technologies' xCELLigence Real-Time Cell Analysis (RTCA) technology was instrumental in developing and validating the potency assay for Autolus Therapeutics' newly FDA-approved CAR T therapy AUCATZYL®.
Autolus Therapeutics Advances Obe-cel into Pivotal Phase 2 Trial for Systemic Lupus Erythematosus
Preliminary Phase 1 data from CARLYSLE trial shows promising efficacy in refractory systemic lupus erythematosus patients, with complete renal responses observed by month three and resolution of key symptoms.
FDA Approves Autolus' Aucatzyl, a CD19 CAR T-cell Therapy for B-cell ALL
The FDA has granted approval to Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel), a CD19 CAR T-cell therapy, for the treatment of B-cell acute lymphoblastic leukemia (ALL).
FDA Approves Autolus' CAR-T Cell Therapy Aucatzyl for Relapsed/Refractory B-ALL
The FDA has approved Autolus Therapeutics' Aucatzyl, a CAR-T cell therapy, for treating relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in adults.
FDA Approves Aucatzyl for Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
The FDA has approved Aucatzyl (obecabtagene autoleucel) for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).
FDA Approves Autolus' CAR-T Therapy AUCATZYL for Relapsed/Refractory B-ALL
Autolus Therapeutics' AUCATZYL (obecabtagene autoleucel) receives FDA approval for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
Obe-cel Demonstrates High Response Rate and Low Toxicity in Adult B-ALL
Obecabtagene autoleucel (obe-cel) shows a 76.6% overall response rate in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL) patients in the FELIX study.
Autolus Therapeutics' AUCATZYL® (obecabtagene autoleucel) Receives FDA Approval for Adult B-cell ALL
Autolus Therapeutics' AUCATZYL® (obecabtagene autoleucel) has been approved by the FDA for treating adult B-cell Acute Lymphoblastic Leukemia (B-ALL).
Autolus' AUCATZYL® (obecabtagene autoleucel) Approved by FDA for Adult B-cell ALL
Autolus Therapeutics' AUCATZYL® (obecabtagene autoleucel) receives FDA approval for relapsed or refractory adult B-cell acute lymphoblastic leukemia (B-ALL).